← Back to headlines
UBS Boosts Bristol-Myers Squibb Price Target Ahead of Milvexian Data
UBS has increased its price target for Bristol-Myers Squibb (BMY) as the market anticipates upcoming data for its drug Milvexian.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
